Keyphrases
Multiple Myeloma
100%
United States Veterans
53%
Diffuse Large B-cell Lymphoma (DLBCL)
52%
Overall Survival
51%
Venous Thromboembolism
46%
Confidence Interval
45%
Obesity
41%
United States
41%
Choosing Wisely
40%
Chemotherapy
40%
Peripheral T-cell Lymphoma
36%
Hematologic Tests
32%
Veterans Health Administration
31%
Rituximab
29%
Lymphoma Patients
27%
Relapsed or Refractory
25%
Abiraterone
24%
Enzalutamide
24%
Adverse Reactions
24%
Monoclonal Gammopathy of Undetermined Significance
24%
US Veterans
21%
Prostate Cancer
20%
Hazard Ratio
20%
Non-Hodgkin Lymphoma
19%
Multicenter Cohort Study
19%
Follicular Lymphoma
19%
Lenalidomide
19%
Programmed Death-ligand 1 (PD-L1)
19%
Doxorubicin
18%
Lymphoma
17%
North America
17%
Clinical Characteristics
17%
American Society of Hematology
17%
Hodgkin Lymphoma
17%
Cutaneous T-cell Lymphoma
17%
Comorbid Diseases
17%
Epoetin Alfa
16%
Body Mass Index
16%
Newly Diagnosed
16%
Weight Change
16%
Natural Killer T-cell Lymphoma
16%
Comparative Effectiveness
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Institutional Experience
16%
Extranodal NK-T-cell Lymphoma
16%
Extranodal
16%
Multi-institutional
16%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
16%
Progressive multifocal Leukoencephalopathy
16%
Cancer-related Anemia
16%
Medicine and Dentistry
Multiple Myeloma
90%
Malignant Neoplasm
58%
Overall Survival
49%
Venous Thromboembolism
46%
Adverse Event
46%
Chemotherapy
44%
Clinician
40%
Health Care Cost
39%
Diseases
36%
Peripheral T-Cell Lymphoma
35%
Diffuse Large B-Cell Lymphoma
33%
Blood Examination
32%
Monoclonal Gammopathy of Undetermined Significance
32%
Computer Assisted Tomography
28%
Cohort Analysis
28%
Non-Hodgkin Lymphoma
26%
Prostate Cancer
26%
Clinical Trial
25%
Internal Medicine
25%
Hematology
24%
Hazard Ratio
21%
Programmed Death 1 Receptor
20%
Non Small Cell Lung Cancer
19%
Retrospective Cohort Study
19%
Lenalidomide
19%
Thrombosis
19%
Rituximab
18%
Follicular Lymphoma
18%
Hodgkin's Lymphoma
17%
Cutaneous T Cell Lymphoma
17%
Mycosis fungoides
16%
Immune Checkpoint Inhibitor
16%
Myeloma
16%
Erythrocyte
16%
CHOP
16%
Prothrombin Complex
16%
NK T Cell Lymphoma
16%
Diabetes Mellitus
16%
Inferior Vena Cava Filter
16%
Thrombophilia
16%
Vitamin K Antagonist
16%
Sarcopenia
16%
Quality Improvement
16%
Glycon
16%
Recombinant Erythropoietin
16%
Body Weight Change
16%
Pancreas Cancer
16%
T-Cell Lymphoma
16%
Odds Ratio
15%
Neoplasm
15%